logo-loader
viewIndivior PLC

Indivior agrees settlement with Mylan Pharma in generics patent dispute over its heroin addiction treatment

Indivior filed patent lawsuits against Mylan, among others, after a Delaware court issued a ruling at the beginning of September finding that Indian generics firm Dr Reddy's Laboratories Inc had not infringed the UK firm’s patents for the product

Suboxone film
Indivior saw more than £1bn wiped off its value on September 1 after losing the legal battle to protect its best-selling product from copycat competition

Indivior PLC (LON:INDV)  has  agreed a settlement with Mylan Pharmaceuticals Inc (NASDAQ:MYL) to resolve a patent dispute over its heroin addiction treatment, Suboxone sublingual film, around a month after being dealt a blow in another US patent action over the product.

In a statement, the FTSE 250-listed firm said the settlement agreed by its US subsidiary, alongside Monosol Rx LLC, with Mylan Pharmaceuticals Inc, Mylan Technologies Inc, and Mylan NV was on confidential terms.

READ: Indivior rearguard begins as it moves to protect its top-selling drug

Indivior filed patent lawsuits against Mylan, among others, earlier this month, for patent infringement of patents related to Suboxone, after a Delaware court issued a ruling at the beginning of September finding that Indian generics firm Dr Reddy's Laboratories Inc had not infringed the UK firm’s patents for the product.

Indivior’s chief executive officer, Shaun Thaxter said today: "The agreement at once reflects our desire to create further certainty for Indivior and underscores the strength of our intellectual property.

“Further, as recently demonstrated with our newly granted '454 patent, we expect to expand the intellectual property estate for Suboxone Film and vigorously assert and defend it.”

Indivior saw more than £1bn wiped off its value on September 1 after losing the legal battle to protect its best-selling product from copycat competition.

READ: Indivior investors see £1bn wiped from the value of the company after US legal setback

It launched a legal rearguard action two weeks later, filing patent infringement lawsuits against Dr Reddy's, Actavis, Par, Alvogen, Teva, and Mylan, and said it was ready to appeal the earlier Dr Reddy’s ruling.

Suboxone film is the company’s biggest selling product and responsible for 90% of its revenues.

Quick facts: Indivior PLC

Price: 34.68 GBX

LSE:INDV
Market: LSE
Market Cap: £253.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Bulls, Bears & Brokers: Alto Capital’s Tony Locantro on Nyrada IPO and small...

Alto Capital investment manager and stock market commentator Tony Locantro updates Proactive on this week's listing of Nyrada Inc (ASX:NYR), a spin-off of Noxopharm Ltd’s (ASX:NOX). He discusses the reasons for the spin-off, including some of the recent and expected trading patterns. Locantro...

2 days, 12 hours ago

RNS

Notification of FY 2019 Results

6 days, 9 hours ago

Total Voting Rights

2 weeks, 4 days ago

Holding(s) in Company

2 weeks, 4 days ago

Holding(s) in Company

on 12/12/19

Holding(s) in Company

on 11/12/19

Additional Listing

on 10/12/19

2 min read